{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019052","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.041052+00:00","generated_at":"2026-06-08T03:44:36.179341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mustang Bio Q3 net loss narrows to $10.1M; cash drops to $10.3M, raises $4.4M post-quarter","bullets":["Cash and equivalents $10.3M at Sep 30, down from $16.1M at Jun 30 and $76.7M at Dec 31, 2022.","Net loss of $10.1M ($1.23/share) vs $19.0M ($2.42) in Q3 2022; R&D expenses fell to $9.5M.","CFIUS review of uBriGene asset sale restarted; new 45-day review period began Nov 14, lease transfer delayed.","MB-106 CAR-T showed 95% ORR in follicular lymphoma (n=20) and two complete responses in WM patients.","FDA accepted IND for MB-109 (MB-101 + MB-108) for recurrent glioblastoma; Phase 1 trial planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019052","json":"https://secwatch.observer/filing/0001558370-23-019052.json","markdown":"https://secwatch.observer/filing/0001558370-23-019052.md","text":"https://secwatch.observer/filing/0001558370-23-019052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/0001558370-23-019052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/tmb-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:44:36.179341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aef80c8f93a7231562617ee48517e54c4008e303","claim":"MUSTANG BIO, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023, EPS $1.23 per share.","evidence_excerpt":"Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/0001558370-23-019052-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders was $10.1 million, or $1.23 per share, for the third quarter of 2023"},{"label":"EPS","value":"$1.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}